Head & Neck/Thyroid Cancers
Latest News
Cancer care and COVID-19 in Seattle, the first U.S. epicenter
Article
How is oncology adapting to COVID-19?
News
Disruptions in cancer care in the era of COVID-19
Conference Coverage
RT plus checkpoint blockade active in head and neck cancer
At 2 years, the progression-free survival rate was 71%, and the overall survival rate was 75%.
News
Lenvatinib/pembrolizumab has good activity in advanced RCC, other solid tumors
Two-thirds of patients with advanced renal cell carcinoma had a clinical response to the TKI/immune checkpoint inhibitor combination.
Latest News
Multimodal therapies almost double survival in anaplastic thyroid cancer
CHICAGO – One cancer center’s experience shows that a targeted, multidisciplinary approach makes a difference.